The biotech firm raised its full-year revenue outlook after Q2 revenue reached $151 million, including a $1.6 million settlement item.
10x Genomics increased its 2026 revenue guidance to a range of $610 million to $630 million, citing sustained demand for its Atera systems, which shipped around 40 units in the quarter. The update follows second-quarter revenue of $151 million, aligning with market expectations.
Management noted a one-time $1.6 million license and royalty revenue from a settlement with Takara, which contributed to the quarter’s results. The prior outlook and consensus estimates were not disclosed, but the revised forecast reflects confidence in continued growth.
Shares showed limited immediate reaction, as investors digested the mixed signals of strong shipments offset by nonrecurring revenue items.